Literature DB >> 8373487

Conflicts of interest and commercialization of research.

S G Korenman1.   

Abstract

The author introduces questions about the commercialization of science, focusing on fairness and conflicts of interest, and suggests the bases for policy initiatives. First, is it fair for government-supported research to enrich research universities and individual scientists? The belief that it is unfair seems limited to biomedicine and is not shared by other fields and government research agencies. The main concerns, however, are conflicts of interest and of commitment (loss of objectivity, reordering of priorities, degradation of science as an open and collegial enterprise, conflicts of commitment, and exploitation of graduate students and postdoctoral fellows). The author outlines 11 principles that can be used in setting policies about conflict of interest and commitment, including the principles that these conflicts are inevitable, that technology transfer should be supported rather than hindered, that the type and amount of financial reward received by the faculty are not as important as the strings attached by the commercial sponsor, and that trainees must be protected from working in settings where they cannot discuss or promptly publish their work.

Entities:  

Keywords:  Biomedical and Behavioral Research; National Institutes of Health

Mesh:

Year:  1993        PMID: 8373487     DOI: 10.1097/00001888-199309000-00029

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  2 in total

1.  Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators.

Authors:  Kevin P Weinfurt; Joëlle Y Friedman; Michaela A Dinan; Jennifer S Allsbrook; Mark A Hall; Jatinder K Dhillon; Jeremy Sugarman
Journal:  J Law Med Ethics       Date:  2006       Impact factor: 1.718

2.  Effects of disclosing financial interests on attitudes toward clinical research.

Authors:  Kevin P Weinfurt; Mark A Hall; Michaela A Dinan; Venita DePuy; Joëlle Y Friedman; Jennifer S Allsbrook; Jeremy Sugarman
Journal:  J Gen Intern Med       Date:  2008-04-02       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.